Navigation Links
MAP Pharmaceuticals Appoints H. Ward Wolff to Board of Directors
Date:3/25/2008

MOUNTAIN VIEW, Calif., March 25 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of financial executive H. Ward Wolff to its board of directors. Mr. Wolff brings over 25 years of financial experience to the board, where he will also serve on the audit committee.

Mr. Wolff is currently Executive Vice President and Chief Financial Officer at Richmond, Calif.-based Sangamo BioSciences, Inc. where he oversees the company's administrative, financial and business development activities and operations. He is also a member of the board of directors of Portola Pharmaceuticals, Inc.

"We are privileged to welcome someone with the depth and breadth of financial experience and knowledge of our industry that Ward brings to our board of directors and audit committee," said Timothy S. Nelson, President and Chief Executive Officer of MAP Pharmaceuticals. "We look forward to benefitting from his expertise as we advance our lead product candidates through clinical development and potential commercialization."

Mr. Wolff was previously Senior Vice President, Finance and CFO at Nuvelo, Inc., and Senior Vice President, Finance and CFO at Abgenix, Inc. until it merged with Amgen Inc. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and CFO of DoubleTwist, Inc., a life sciences company. He began his career with Price Waterhouse, where he held a number of positions as a certified public accountant.

Mr. Wolff received an M.B.A. from Harvard Business School and a B.A. in Economics from the University of California, Berkeley.

About MAP Pharmaceuticals, Inc.

MAP Pharmaceuticals develops and plans to commercialize new therapies for children and adults who suffer from chronic conditions that it believes are not adequately treated by currently available medicines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
2. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
3. Dreier LLP Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated (VRTX)
4. Alseres Pharmaceuticals, Inc. Raises $5 Million
5. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
6. Transcept Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
7. Law Offices of Howard G. Smith Announces Class Action Lawsuit Against Vertex Pharmaceuticals Incorporated
8. Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
9. Waters Offers U.S. Water Authorities Complimentary Drinking Water Testing for the Presence of Pharmaceuticals
10. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
11. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... that have new attractive animation styles with unique displacement design elements," said Christina ... pre-animated lower third designs. Choose from a variety of design styles that include ...
(Date:12/4/2016)... PITTSBURGH, PA (PRWEB) , ... December 04, 2016 , ... ... not enough. One must brush properly to achieve optimal results. This important necessity inspired ... saw a need for a way to ensure that people break or avoid bad ...
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s ... help provide scholarship funds for area students and operating support to UNCF-member institutions, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016  John Seng, founder of ... will succeed him as Chief Executive Officer following two consecutive years ... Wilson joined Spectrum as president in 2014 and assumed management of ... received public relations industry recognition as Healthcare Agency of the Year ... ...
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated to reach USD ... Research, Inc. Evolution of prenatal testing in the form of noninvasive tests ... diagnostic testing to determine the likelihood of fetal abnormality is expected to ... Continue Reading ... ...
Breaking Medicine Technology: